What happens on injection day

Most patients leave the clinic unaided within an hour of arriving — no crutches, no wound dressing, no overnight stay. ChondroFiller is placed as a single outpatient injection under ultrasound guidance, without general anaesthetic or an incision. Once the needle is withdrawn, the collagen material gels in situ within approximately three to five minutes, conforming to the shape of the cartilage defect.

The rest of injection day is straightforward. Some localised soreness or a sense of fullness in the treated knee is common in the first 24–48 hours; this reflects the scaffold settling into place and is self-limiting rather than a sign of a problem. Paracetamol is the first-line choice for discomfort. Short-course ibuprofen can help with inflammation if needed for the first two to three days, though clinicians generally advise checking with the treating team before using NSAIDs, as anti-inflammatories may interfere with the early healing environment.

Driving should be avoided for at least 24 hours after the injection — longer if the procedure involved the right knee or the vehicle is a manual. Beyond that, normal light activity around the home is appropriate from the evening onwards.

Weeks 1–6: protecting the scaffold while it stabilises

The collagen scaffold gels within minutes, but gelling is not the same as being anchored. Until the body's own progenitor cells migrate into the matrix — a process called acellular matrix-induced chondrogenesis — the scaffold remains mechanically vulnerable to displacement. That cell ingrowth takes weeks, which is why the first six weeks carry the most specific guidance.

Weeks 1–2: reducing compressive load

Full compressive loading — sustained standing, stair-climbing, and carrying heavy weight through the joint — should be avoided during the first fortnight. The scaffold needs that window to begin integrating with surrounding tissue before it can reliably tolerate those forces. Light daily movement is actively encouraged: gentle walking on flat ground helps circulate synovial fluid and keeps the joint from stiffening. The goal is protection, not immobility.

Week 3: hold the same course

Week three sits between the two main phases and the guidance carries over unchanged from week two. Most patients find this the point at which soreness has largely settled and the temptation to do more is greatest — which is precisely the moment to stay cautious.

Weeks 4–6: consolidation and first review

Through weeks four to six, progenitor cells from the synovium and subchondral bone progressively anchor the scaffold, converting it into a stable implant. High-impact activity and repeated heavy loading remain off the agenda during this window. A follow-up appointment — typically included in the treatment package — is usually scheduled within this period so the treating clinician can assess how well the scaffold is integrating and agree the next step in rehabilitation. Progression beyond week six is guided by that clinical assessment rather than the calendar alone.

The six-week review and what it covers

At that six-week consultation, the clinician is not looking for visible cartilage repair — full scaffold resorption and cell-driven tissue replacement unfolds over twelve to twenty-four months. What the assessment covers is integration: whether the scaffold has stabilised, whether local inflammation has settled, and whether the joint is ready to accept more progressive loading.

The pace that follows is individual. Defect size, the condition of surrounding cartilage, and each person's tissue response all influence how quickly activity can increase — no fixed calendar applies. For most patients whose assessment is straightforward, the conversation at review centres on introducing low-impact activity in the weeks ahead: flat-surface walking extended gradually to around thirty minutes, for instance, or stationary cycling at light resistance. These are starting points rather than targets.

Where there are signs of persistent inflammation or slower integration, the protective phase simply continues a little longer. That is not an unusual outcome — it reflects a clinical decision to give the scaffold the time it needs rather than any individual failure to heal well.

Months 1–12: activity milestones as repair progresses

Recovery through the remainder of the first year follows a broadly predictable sequence of milestones, each paced to the biology of the repair rather than to how the knee feels on any given day.

From week six to month four, the focus is on steadily extending low-impact movement. Flat-surface walking builds toward thirty minutes or more; stationary cycling at light resistance and swimming can typically be introduced during this window once the six-week review has confirmed scaffold integration. Stair-climbing and sustained standing become easier as the repair tissue matures, though the joint still benefits from avoiding high-impact loads.

Around month four, most patients are in a position to begin more structured low-impact exercise — cycling outdoors, pool lengths, or an elliptical trainer — as the collagen scaffold progressively gives way to the body's own repair tissue.

Strenuous exercise, high-impact activity, and contact sport are generally not recommended until approximately one year post-injection. That is the point at which the scaffold has been largely replaced by progenitor-cell-derived repair tissue, and the regenerated surface is more reliably able to tolerate the shear and compressive forces those activities impose.

The schedule matters most during the months when patients feel better than they might have anticipated. A small published series of 17 knee patients showed IKDC function scores improving meaningfully at three and six months, then reaching a consolidation plateau with no statistically significant further change between months six and twelve. Symptomatic gains, in other words, tend to arrive before structural maturation is complete. The repair tissue continues forming and remodelling within the scaffold for up to twelve to twenty-four months — a biological process that is clinically silent but structurally significant. Loading the joint heavily during that window, on the basis that it feels recovered, risks disrupting a repair that has not yet fully consolidated. The milestone schedule is not a conservative estimate; it reflects that divergence between how the knee feels and what the tissue can sustain.

What outcomes evidence shows — and where gaps remain

The headline figure across published follow-up — 70–85% of patients reporting meaningful symptom relief at three to five years — holds consistently across knee, hip, and small-joint applications. That breadth of coverage is a reasonable signal of generalisability, though it sits alongside the important qualifier that most studies cover well-selected populations: focal Grade III–IV defects with healthy surrounding cartilage borders, not widespread joint degeneration.

On objective imaging, the picture is similarly encouraging. Post-treatment MRI shows reduction in bone marrow oedema, diminished periarticular effusion, and visible widening of joint space. MOCART scores of 81.6–84.3 in European studies indicate that more than 80% of the treated defect area is filled and integrating with native cartilage. The safety profile reinforces that: the documented complication rate is approximately 0% in well-selected patients, and the reoperation rate of 3–8% compares favourably with published figures for microfracture (around 41%) and ACI/MACI (around 37%). Across more than 19,000 cases performed globally, that pattern has remained consistent.

The more important transparency point concerns the evidence base itself. The bulk of published outcome data — including the IKDC series referenced in the previous section — derives from arthroscopic placement under direct visualisation, where the scaffold is delivered into a precisely prepared defect under controlled surgical conditions. The ultrasound-guided outpatient injection pathway is the current clinical service, but it is a different delivery mode, and no rigorous randomised controlled trial specific to that route has been identified. Expectations for the injection pathway are therefore cautiously extrapolated from the arthroscopic literature rather than drawn from a matched evidence base of their own. The underlying biology of the scaffold does not change with delivery route, but patients reviewing the data should understand where it originates.

Who tends to do best and when to seek specialist assessment

Consistently better outcomes are associated with a specific clinical profile: a focal cartilage defect graded III or IV, healthy surrounding cartilage borders, and no significant widespread osteoarthritis elsewhere in the joint. Younger, active patients with a discrete, contained lesion represent the clearest indication in published series — though age alone is not the deciding factor.

Several situations make ChondroFiller less likely to be appropriate. Multiple diffuse defects, significant joint malalignment, or advanced degeneration that has spread beyond a focal area generally point toward a different management pathway. The scaffold supports matrix-induced chondrogenesis within a contained defect; it is not a substitute for joint replacement in end-stage arthritis, and should not be presented as one.

Self-selection based on symptoms alone is unreliable. A specialist assessment — including review of recent MRI — is needed to determine whether a defect's size, depth, border condition, and surrounding joint status make the ultrasound-guided injection pathway appropriate. Clinical history, activity level, and biomechanical factors all inform that judgement.

Patients considering whether they may be suitable candidates can arrange a cartilage assessment through London Cartilage Clinic, where the imaging and clinical picture are reviewed before any treatment decision is made.